Please enable Javascript
Knowledge Hubs
The latest news on genitourinary oncological disease states.
Prostate Cancer Knowledge Hubs
Prostate Cancer
Localized
mCSPC
CRPC
RLT
Prostate Cancer Diagnostics
Prostate Cancer
Localized
mCSPC
CRPC
Advertisement
Renal Cell Carcinoma Knowledge Hubs
Renal Cell Carcinoma
Localized Renal Cell Carcinoma
Advanced Renal Cell Carcinoma
nccRCC
Renal Cell Carcinoma Diagnostics
Renal Cell Carcinoma
Localized Renal Cell Carcinoma
Advanced Renal Cell Carcinoma
nccRCC
Advertisement
Urothelial Carcinoma Knowledge Hubs
Urothelial Carcinoma
Non-Muscle Invasive Urothelial Carcinoma
Muscle Invasive Urothelial Carcinoma
Advanced Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Urothelial Carcinoma Diagnostics
Urothelial Carcinoma
Non-Muscle Invasive Urothelial Carcinoma
Muscle Invasive Urothelial Carcinoma
Advanced Urothelial Carcinoma
Testicular, Penile, and Rare Malignancies Knowledge Hubs
Testicular, Penile, and Rare Malignancies
Testicular, Penile, and Rare Malignancies
Roundtable Discussions
What’s Next for RCC Treatment? Promising New Targets and Clinical Trials
Katy Beckermann, MD, PhD
Roundtable
|
November 18, 2024
The panelists discuss promising new advancements and novel therapies for treating RCC, including LAG-3 and CAR-T therapies.
The Future of RCC Treatment Sequencing and Individualized Patient Care
Katy Beckermann, MD, PhD
Roundtable
|
November 18, 2024
The panel discusses how designing effective trials could refine the approach to treatment strategies for RCC.
Navigating Treatment Sequencing and Toxicity in RCC: Insights From TiNivo-2
Katy Beckermann, MD, PhD
Roundtable
|
November 18, 2024
Part 3 of this roundtable examines adjuvant pembrolizumab and the role of TKIs in treatment sequencing for RCC.
TiNivo-2 Efficacy: Breaking Down the Data on TKI and Immunotherapy in RCC Treatment
Katy Beckermann, MD, PhD
Roundtable
|
November 18, 2024
The panelists examine the data on TKIs and immunotherapy for RCC from the TiNivo-2 trial.
TiNivo-2 vs CONTACT-03: Trial Design and Key Differences
Katy Beckermann, MD, PhD
Roundtable
|
November 18, 2024
Part 1 of this roundtable examines the key differences between the CONTACT-03 and TiNivo-2 trials.
The Rise of Immunotherapy in Prostate Cancer
Irbaz B. Riaz, MBBS, PhD
SPCS 2024
|
November 5, 2024
In part six of this roundtable series, the panelists finish their discussion by reviewing immunotherapy in prostate cancer.
View Full Archive
Advertisement
Advertisement
Editorial Advisory Board
Brian Rini, MD, FASCO
Editor | Chief of Clinical Trials at Vanderbilt-Ingram Cancer Center
Thomas Powles, MBBS, MRCP, MD
Editor | Director, Barts Cancer Centre at St. Bartholomew's Hospital
Catherine H. Marshall, MD, MPH
Editor | Assistant Professor of Oncology at the Johns Hopkins University School of Medicine
Jérémie Calais, MD, PhD
Editor | Director of the Theranostics and Clinical Research Programs at the University of California, Los Angeles
Akhil Abraham Saji, MD
Editor | Urologist at Swedish Health Services
David Ambinder, MD
Editor | Urology Resident at New York Medical College/Westchester Medical Center